Wilson Therapeutics
Developing novel treatments for Wilson Disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 35639.3x EV/Revenue | round | |
| N/A | €0.0 | round | |
$855m Valuation: $855m 5121.4x EV/Revenue -21.8x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | 393745 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (23487 %) | 97 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (202278 %) | - | - | (22847 %) | 98 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Wilson Therapeutics, now part of Alexion Pharmaceuticals, is a biopharmaceutical company dedicated to developing transformative therapies for individuals suffering from rare and severe diseases. The company primarily serves patients with limited treatment options, focusing on conditions that are often overlooked by larger pharmaceutical firms. Operating within the niche market of rare diseases, Wilson Therapeutics employs a business model centered around research and development, clinical trials, and strategic partnerships. Revenue is generated through the commercialization of its proprietary therapies, often in collaboration with third-party companies in select countries to manage local commercial operations. By addressing unmet medical needs, Wilson Therapeutics aims to create significant value for patients and their families, ultimately improving their quality of life.
Keywords: biopharmaceutical, rare diseases, transformative therapies, clinical trials, niche market, strategic partnerships, proprietary therapies, patient-focused, innovative solutions, Alexion Pharmaceuticals.